Clinical Trial Update: Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial [Phase 2]

View source ↗

Summary

A randomized Phase IIb trial comparing belotecan with topotecan for recurrent epithelial ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer

Drugs mentioned

• Belotecan (Belotecan)
• Topotecan (topotecan)

Snippet

Sponsor: Chong Kun Dang Pharmaceutical | Conditions: Epithelial Ovarian Cancer | Phase 2 | Status: COMPLETED